BI_689648_HNMR_27086_MedChemExpress
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
TMA-DPH-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Mar.-25-2019Print Date:Mar.-25-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :TMA-DPHCatalog No. :HY-D0986CAS No. :115534-33-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C28H31NO3SMolecular Weight:461.62CAS No. :115534-33-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: -20°C, protect from lightShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
凝胶色谱法测定美罗培南中的聚合物
０２、．、． ０８ １ １ ． ０４ ０６、．、． ． ｍＬ置 ２ ０、 ２ ５ｍＬ量 瓶 中 ， 流 动 相 稀 释 用
至 刻度 ， 摇匀 ， 作为 供试 品溶 液 。 照美 岁 培南 含量 测定 项下 方
图 １ 聚 合物 对 照品 溶 液 与 峰 面 积 线 性
照 溶 液 和 供 试 品溶 液 中 聚合 物 峰 的 保 留 时 间 比为 １ ２ 供 ． ， ０ 试 品 中葡 聚糖 于单 体 问分 离度 ≥１５ ． 。均 符 合 系统 适 用性 要 求。
２２溶 液 的 配 制 ．
本身 引起 ， 而是 和药 物 中存 在 的高分 子杂 质有 关 ［］因此 ， 】。 － ２ 控
ｆ 键 词 】美 罗培 南 ； 合 物 ； 胶 色谱 法 ； 定 关 聚 凝 测
『 分类 号】 ２ ６０ 中图 Ｒ ８ ．
［ 标识 码】 文献 Ａ
【 章编 号】 ６ ４ ４ ２ （０ ２ Ｏ （ ）０ ５ — ２ 文 １ ７ — ７ １２ １ ）４ ｂ 一 ０ ５ ０
Ｄ ｅｅ ｍ ｉ ｔｏ ｏ ｇ ｏ ｙ ｅ Ｍ ｅ ｏ ｎｅ ｙ ｇ ｌ ｌｒ ｔｏ ｈｒ ｍ ａ ｏ ｒ ｐｈ ｔ ｒ ｎａ ｉ ｎ ｆ ｈｉ ｈ ｐ ｌ ｍ ｒｉ ｎ ｒ ｐｅ ｍ ｂ ｅ ｔ ａ ｉ ｎ ｃ ｏ ｉ ｆ ｔｇ ａ ｙ
高效液相色谱法测定草酸艾司西酞普兰片的含量
高效液相色谱法测定草酸艾司西酞普兰片的含量代亚;付涛;俞丽君;陈立萍;王贤广【摘要】目的采用高效液相色谱法测定草酸艾司西酞普兰片的含量.方法色谱柱为C18柱(250 mm×4.6 mm,5 μm),流动相为磷酸缓冲液-甲醇(51 ∶49),检测波长为238 nm.结果艾司西酞普兰质量浓度在25 ～150 μg/mL范围内与峰面积呈良好线性关系(r＝0.999 9),平均回收率为99.60%,RSD为0.44%.结论该方法简便,专属性及重现性好,可用于测定草酸艾司西酞普兰片的含量.【期刊名称】《中国药业》【年(卷),期】2011(020)016【总页数】2页(P32-33)【关键词】草酸艾司西酞普兰片;含量测定;高效液相色谱法【作者】代亚;付涛;俞丽君;陈立萍;王贤广【作者单位】浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104【正文语种】中文【中图分类】R927.2;R971+.43自从1985年第1个5－羟色胺再吸收抑制剂(SSRIs)上市以来，其在临床得到了广泛应用。
这类药物不产生三环类抗抑郁药的抗副交感神经作用、低血压、认知障碍或镇静等副作用，是一类性能优良的抗抑郁药。
草酸艾司西酞普兰(escitalopram oxalate)就是其中的一种，它是消旋体药物西酞普兰(由 R－西酞普兰和 S－西酞普兰按1∶1的比例组成)的 S－西酞普兰，S－西酞普兰药效优于R－西酞普兰[1]。
该药是由丹麦的Lundbeck公司首先研究开发，2002年8月首次被美国食品与药物管理局(FDA)批准，主要用于重型抑郁障碍的初始治疗和维持治疗。
笔者采用高效液相色谱(HPLC)法测定草酸艾司西酞普兰片的含量，按照2010年版《中国药典(二部)》附录中药品质量标准分析方法验证指导原则[2]进行了方法学试验，现报道如下。
重组贻贝粘蛋白的表征及功效评价
生物技术进展 2023 年 第 13 卷 第 4 期 596 ~ 603Current Biotechnology ISSN 2095‑2341研究论文Articles重组贻贝粘蛋白的表征及功效评价李敏 ， 魏文培 ， 乔莎 ， 郝东 ， 周浩 ， 赵硕文 ， 张立峰 ， 侯增淼 *西安德诺海思医疗科技有限公司，西安 710000摘要：为了推进重组贻贝粘蛋白在医疗、化妆品领域的应用，对大肠杆菌规模化发酵及纯化生产获得的重组贻贝粘蛋白进行了表征及功效评价。
经Edman 降解法、基质辅助激光解吸电离飞行时间质谱、PITC 法、非还原型SDS -聚丙烯酰胺凝胶电泳法、凝胶法、改良的Arnow 法对重组贻贝粘蛋白进行氨基酸N 端测序、相对分子量分析、氨基酸组成分析、蛋白纯度分析、内毒素含量测定、多巴含量测定；通过细胞迁移、斑马鱼尾鳍修复效果对重组贻贝粘蛋白进行功效评价。
结果显示，获得的重组贻贝粘蛋白与理论的一级结构一致，蛋白纯度达95%以上，内毒素<10 EU ·mg -1,多巴含量大于5%；重组贻贝粘蛋白浓度为60 μg ·mL -1时能够显著促进细胞增殖的活性（P <0.01）；斑马鱼尾鳍面积样品组与模型对照组相比极显著增加（P <0.001）。
研究结果表明，重组贻贝粘蛋白具有显著的促细胞迁移和修复愈合的功效，具备作为生物医学材料的潜质。
关键词：贻贝粘蛋白；基因重组；生物材料；表征；功效评价DOI ：10.19586/j.20952341.2023.0021 中图分类号：S985.3+1 文献标志码：ACharacterization and Efficacy Evaluation of Recombinant Mussel Adhesive ProteinLI Min ， WEI Wenpei ， QIAO Sha ， HAO Dong ， ZHOU Hao ， ZHAO Shuowen ， ZHANG Lifeng ，HOU Zengmiao *Xi'an DeNovo Hith Medical Technology Co.， Ltd ， Xi'an 710000， ChinaAbstract ：In order to promote the application of recombinant mussel adhesive protein in the medical and cosmetics field ， the recombi⁃nant mussel adhesive protein obtained from scale fermentation and purification of Escherichia coli was characterized and its efficacy was evaluated. Amino acid N -terminal sequencing ， relative molecular weight analysis ， amino acid composition analysis ， protein purityanalysis ， endotoxin content ， dihydroxyphenylalanine （DOPA ） content of recombinant mussel adhesive protein were determined by the following methods ： Edman degradation ， matrix -assisted laser desorption ionization time -of -flight mass spectrometry （MALDI -TOF -MS ）， phenyl -isothiocyanate （PITC ）， nonreductive SDS -polyacrylamide gel electrophoresis （SDS -PAGE ）， gel method ， modified Ar⁃now. The efficacy of recombinant mussel adhesive protein was evaluated by cell migration and repairing effect of zebrafish tail fin. Re⁃sults showed that the obtained recombinant mussel adhesive protein was confirmed to be consistent with the theoretical primary structure ， protein purity of more than 95%， endotoxin <10 EU ·mg -1， DOPA content above 5%. When the recombinant mussel adhesive protein concentration was 60 μg ·mL -1， the effect of promoting cell proliferation was the most obvious ， and it had very significant activity （P <0.01）. The caudal fin area of zebrafish in sample group was significantly increased compared with model control group （P <0.001）. The results indicated that recombinant mussel adhesive protein can promote cell migration and repair healing and has the potential to be used as biomedical materials.Key words ：mussel adhesive protein ； gene recombination ； biological materials ； representation ； efficacy evaluation贻贝粘蛋白（mussel adhesive protein ， MAP ）也称作贻贝足丝蛋白（mussel foot protein ，Mfps ），收稿日期：2023⁃02⁃24； 接受日期：2023⁃03⁃31联系方式：李敏 E -mail:*******************;*通信作者 侯增淼 E -mail:***********************.cn李敏，等：重组贻贝粘蛋白的表征及功效评价是海洋贝类——紫贻贝（Mytilus galloprovincalis）、厚壳贻贝（Mytilus coruscus）、翡翠贻贝（Perna viri⁃dis）等分泌的一种特殊的蛋白质，贻贝中含有多种贻贝粘蛋白，包括贻贝粘蛋白（Mfp 1～6）、前胶原蛋白（precollagens）和基质蛋白（matrix proteins）等［1］。
广藿香抑制肠推进药效指纹图谱构建与谱效关系研究
Ｃｏ ｎ ｓ ｔ ｒ ｕ ｃ ｔ ｉ ｏ ｎ ｏ ｆ ｐ ｈ ａ ｒ ｍａ ｃ ｏ ｄ ｙ ｎ ａ ｍｉ ｃ ｉ ｆ ｎ ｇ ｅ ｒ ｐ ｒ ｉ ｎ ｔ ａ ｎ ｄ ａ ｎ ａ ｌ ｙ ｓ ｉ ｓ ｏ ｆ ｓ ｐ ｅ ｃ ｔ ｒ ｕ ｍ－
ｅ ｆ ｆ ｅ ｃ ｔ ｒ ｅ ｌ ａ ｔ ｉ ｏｎ ｓ ｈｉ ｐ ｏ ｎ ａ ｎｔ ｉ —ｇ ａ ｓ ｔ ｒ ０ ｉ ｎｔ ｅ ｓ ｔ ｉ ｎａ ｌ ｐｒ ｏ ｐ ｕｌ ｓ ｉ ｖ ｅ ｏ ｆ Ｈｅ ｒ ｂａ Ｐｏ ｇ ｏ ｓ ｔ ｅ －
ｗ ｉ ｔ ｈ ａ ｎ ｔ ｉ － ｇ ａ ｓ ｔ ｒ ｏ ｉ ｎ ｔ ｅ ｓ ｔ ｉ ｎ ａ ｌ ｐ ｒ ｏ ｐ ｕ ｌ ｓ ｉ ｖ ｅ ｍｏ ｔ ｉ ｌ ｉ ｔ ｙ ． Ｍｅ ｔ ｈ ｏ ｄ ｓ Ｈｅ ｒ ｂ ａ Ｐ ０ ｇ ｏ ｓ ｔ ｅ ｍｏ ｎ ｉ ｓ ｗａ ｓ ｅ ｘ ｔ ｒ ａ ｃ ｔ ｅ ｄ ｒ ｅ ｓ ｐ ｅ ｃ ｔ ｉ ｖ ｅ ｌ ｙ ｂ ｙ ｅ ｔ ｈ ｙ ｌ ａ ｃ ｅ ｔ ａ ｔ ｅ ， ａ ｃ ｅ — ｔ ｏ ｎ ｅ ，ｍｅ ｔ ｈ ａ ｎ ｏ ｌ ａ ｎ ｄ ｗ ａ ｔ ｅ ｒ ． Ｅｘ ｔ ｒ ａ ｃ ｔ ｓ ｗｅ ｒ ｅ ｔ ｅ ｓ ｔ ｅ ｄ ｂ ｙ ｇ ａ ｓ ｔ ｒ ｏ ｉ ｎ ｔ ｅ ｓ ｔ ｉ ｎ ａ ｌ ｐ ｒ ｏ ｐ ｕ ｌ ｓ ｉ ｖ ｅ ｅ ｘ ｐ ｅ ｉｍｅ ｒ ｎ ｔ ，ＨＰ Ｌ Ｃ ｉ ｆ ｎ ｇ ｅ ｐｒ ｒ ｉ ｎ ｔ ｗａ ｓ ｓ ｅ ｔ ｕ ｐ ｂ ａ ｓ ｅ ｄ ｏ ｎ ｔ ｈ ｅ ｅ ｘ ｔ ｒ ａ ｃ ｔ ｏ ｆ ｂ ｅ ｓ ｔ ｐ ｈ ａ ｍ ａ ｒ ｃ ｏ ｌ ｏ ｇ ｉ ｃ ａ ｌ ｅ ｆ ｆ ｅ ｃ ｔ ｓ ． Ｔｈ ｅ ｓ ｐ ｅ ｃ ｔ ｒ ｕ ｍ－ ｅ ｆ ｆ ｅ ｃ ｔ ｒ ｅ ｌ ａ ｔ ｉ ｏ ｎ ｓ ｈ ｉ ｐ ｗ ａ ｓ ｓ ｔ ｕ ｄ ｉ ｅ ｄ ｂ ｙ ｇ ｒ ｅ ｙ ｒ ｅ ｌ ａ ｔ ｉ ｏ ｎ ｓ ｔ ａ ｔ ｉ ｓ ｔ ｉ ｃ ． Ｒｅ ｓ ｕ ｌ ｔ ｓ Ｍｅ ｔ ｈ ａ ｎ ｏ ｌ ｅ ｘ ｔ ｒ ａ ｃ ｔ ｓ ｈ ｏ ｗ ｅ ｄ ｓ ｔ ｒ ｏ ｎ ｇ ｅ ｓ ｔ ｉ ｎ ｈ ｉ ｂ ｉ ｔ ｉ ｏ ｎ ｏ ｆ ｇ ａ ｓ ｔ ｒ ｏ ｉ ｎ ｔ ｅ ｓ ｔ ｉ ｎ ａ ｌ ｐ ｒ ｏ ｐ ｕ ｌ ｓ ｉ ｖ ｅ ｍｏ ｔ ｉ ｌ ｉ ｔ ｙ ． Ｏｎ ｔ ｈ ｉ ｓ ｂ ａ ｓ ｉ ｓ ， ｐ ｈ ａ ｒ ｍａ ｃ ｏ ｄ ｙ ｎ ａ ｍｉ ｃ ｆ ｉ ｎ ｇ ｅ ｒ ｐ ｉ ｒ ｎ ｔ ｗｉ ｔ ｈ １ ８ ｃ ｈ ａ ｒ ａ ｃ ｔ ｅ ｉ ｒ ｓ ｔ ｉ ｃ ｐ ｅ ａ ｋ ｓ ｗ ａ ｓ ｓ ｅ ｔ ｕ ｐ ． Ｃｏ ｒｅ ｓ ｐ ｏ ｎ ｄ ｉ ｎ ｇ ｃ ｏ ｍｐ ｏ ｎ ｅ ｎ ｔ ｓ ｏ ｆ Ｐ ５ ， Ｐ １ ０ ， Ｐ１ ２ ， Ｐ１ ３ ａ ｎ ｄ Ｐ１ ４ ｓ ｈ ｏ ｗ ｅ ｄ ｍａ ｘ ｉ ｍｕ ｍ ｃ ｏ ｒｅ ｌ ａ — ｔ ｉ ｏ ｎ ｗ ｉ ｔ ｈ ｐ ｈ ａ ｒ ｍａ ｃ ｏ ｌ ｏ ｇ ｉ ｃ ａ ｌ ｅ ｆ ｆ ｅ ｃ ｔ ｓ ． ｔ ｈ ｅ ｓ ｉ ｚ ｅ ｏ ｒ ｄ ｅ ｒ ｗ ａ ｓ Ｐ１ ４＞ Ｐ１ ３＞ Ｐ ５＞ Ｐ １ ２ ＞Ｐ１ ０ ． Ｃｏ ｎ ｃ ｌ ｕ ｓ ｉ ｏ ｎ Ｔ ｈ ｅ ｐ ｈ ａ ｒ ｍａ ｃ ｏ ｄ ｙ ｎ ａ ｍｉ ｃ ｆ ｉ ｎ ｇ ｅ ｒ — ｐ ｉ ｒ ｎ ｔ ｏ ｆ Ｈｅ ｒ ｂ ａ Ｐ ｏ ｇ ｏ ｓ ｔ ｅ ｍｏ ｎ ｉ ｓ ｓ ｈ ｏ ｕ ｌ ｄ ｓ ｅ ｔ ｕ ｐ ｂ ａ ｓ ｅ ｄ ｏ ｎ ｔ ｈ ｅ ｍｅ ｔ ｈ ａ ｎ ｏ ｌ ｅ ｘ ｔ ｒ ａ ｃ ｔ ． Ｔ ｈ ｅ ａ ｎ ｔ ｉ — ｇ ａ ｓ ｔ ｒ ｏ ｉ ｎ ｔ ｅ ｓ ｔ ｉ ｎ ａ ｌ ｐ ｒ ｏ ｐ ｕ ｌ ｓ ｉ ｖ ｅ ｅ ｆ ｆ ｅ ｃ ｔ ｏ ｆ Ｈｅ ｒ ｂ ａ Ｐ ｏ ｇ ｏ ｓ ｔ ｅ ｍｏ ｎ ｉ ｓ ｉ ｓ ｒ ｅ ｌ ａ ｔ ｅ ｄ ｔ ｏ ａ ｖ ａ ｉｅ ｒ ｔ ｙ ｏ ｆ ｉ ｎ ｇ ｒ ｅ ｄ ｉ ｅ ｎ ｔ ｓ ．
抑制丙肝病毒复制的大环类化合物[发明专利]
![抑制丙肝病毒复制的大环类化合物[发明专利]](https://img.taocdn.com/s3/m/80c723ff866fb84ae55c8d9e.png)
专利名称：抑制丙肝病毒复制的大环类化合物专利类型：发明专利
发明人：李本,陈力,翟培彬,江涛
申请号：CN201280069837.0
申请日：20121205
公开号：CN104169293A
公开日：
20141126
专利内容由知识产权出版社提供
摘要：本发明提供一种式I化合物，其中基团定义如说明书所述。
该化合物作为HCV蛋白酶抑制剂，用于治疗丙肝病毒感染。
申请人：银杏树药业(苏州)有限公司
地址：215123 江苏省苏州市苏州工业园区星湖街218号C11楼3楼
国籍：CN
代理机构：北京航忱知识产权代理事务所(普通合伙)
代理人：张华
更多信息请下载全文后查看。
一种含氟紫杉烷类化合物及其制备方法与应用[发明专利]
![一种含氟紫杉烷类化合物及其制备方法与应用[发明专利]](https://img.taocdn.com/s3/m/d3ffd7f7fc4ffe473268ab78.png)
专利名称：一种含氟紫杉烷类化合物及其制备方法与应用专利类型：发明专利
发明人：景云荣,王春花,张蕾
申请号：CN201810995609.5
申请日：20180829
公开号：CN110143934A
公开日：
20190820
专利内容由知识产权出版社提供
摘要：本发明公开了一种含氟紫杉烷类化合物及其制备方法与应用。
该化合物的结构通式如式I所示。
药理实验证明，本发明所合成的一系列含氟的紫杉烷类衍生物，与紫杉醇相比，对于多药耐药型人乳腺癌细胞株MCF‑7/Adr，卵巢癌细胞株NCI/Adr具有优于紫杉醇的细胞毒性，并且针对肿瘤干细胞过表达的结肠癌细胞株HCT‑116表现出优于紫杉醇的细胞毒性。
申请人：牡丹江师范学院
地址：157011 黑龙江省牡丹江市爱民区文化街191号
国籍：CN
代理机构：北京纪凯知识产权代理有限公司
代理人：关畅
更多信息请下载全文后查看。
一种高效的内切酶缓冲液体系[发明专利]
![一种高效的内切酶缓冲液体系[发明专利]](https://img.taocdn.com/s3/m/fccb4be652ea551811a687b8.png)
专利名称：一种高效的内切酶缓冲液体系专利类型：发明专利
发明人：张长领,刘二凯,陈奥,章文蔚
申请号：CN201780090482.6
申请日：20170801
公开号：CN110869501A
公开日：
20200306
专利内容由知识产权出版社提供
摘要：一种能提高Endo IV酶活性的内切酶缓冲液，包括20~200mM的Tris‑HCl，0.05~0.2M的NaCl，2~20mM的MgSO，0.2~10mM的DTT，0.05~5质量%的表面活性剂，pH为7~8。
所述缓冲液还可进一步包括0.1~5质量%的碳原子数小于5的短链醇类。
申请人：深圳华大智造科技有限公司
地址：518083 广东省深圳市盐田区北山工业区综合楼及11栋2楼
国籍：CN
代理机构：深圳鼎合诚知识产权代理有限公司
更多信息请下载全文后查看。